Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells
Authors:
- 9 August 2020
- journal article
- research article
- Published by Springer Nature in Inflammation
- Vol. 44 (1) , 206-216
Abstract
Sjögren’s syndrome (SS) is a chronic autoimmune disease targeting salivary and lacrimal glands. C-X-C motif chemokine ligand 10 (CXCL10) expression is upregulated in lip salivary glands (LSGs) of primary SS (pSS) patients, and CXCL10 involved in SS pathogenesis via immune-cell accumulation. Moreover, interferon (IFN)-γ enhances CXCL10 production via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. We investigated the effects of baricitinib, a selective JAK1/2 inhibitor, on both IFN-γ-induced CXCL10 production and immune-cell chemotaxis. We used immunohistochemical staining to determine the expression levels and localization of JAK1 and JAK2 in LSGs of SS patients (n = 12) and healthy controls (n = 3). We then evaluated the effect of baricitinib in an immortalized normal human salivary gland ductal (NS-SV-DC) cell line. Immunohistochemical analysis of LSGs from pSS patients revealed strong JAK1 and JAK2 expression in ductal and acinar cells, respectively. Baricitinib significantly inhibited IFN-γ-induced CXCL10 expression as well as the protein levels in an immortalized human salivary gland ductal-cell clone in a dose-dependent manner. Additionally, western blot analysis showed that baricitinib suppressed the IFN-γ-induced phosphorylation of STAT1 and STAT3, with a stronger effect observed in the case of STAT1. It also inhibited IFN-γ-mediated chemotaxis of Jurkat T cells. These results suggested that baricitinib suppressed IFN-γ-induced CXCL10 expression and attenuated immune-cell chemotaxis by inhibiting JAK/STAT signaling, suggesting its potential as a therapeutic strategy for pSS.Keywords
Funding Information
- Grants-in-Aid for Scientific Research program of the Japanese Ministry of Education, Culture, Sports, Science, and Technology (19K10311)
This publication has 25 references indexed in Scilit:
- Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseasesAutoimmunity Reviews, 2014
- Advances in understanding the pathogenesis of primary Sjögren's syndromeNature Reviews Rheumatology, 2013
- Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expressionAnnals of the Rheumatic Diseases, 2013
- Characteristics of the minor salivary gland infiltrates in Sjögren's syndromeJournal of Autoimmunity, 2010
- DNA microarray analysis of labial salivary glands of patients with Sjögren's syndromeAnnals of the Rheumatic Diseases, 2007
- Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjectsArthritis & Rheumatism, 2005
- Involvement of the interferon‐γ–induced T cell–attracting chemokines, interferon‐γ–inducible 10‐kd protein (CXCL10) and monokine induced by interferon‐γ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndromeArthritis & Rheumatism, 2002
- JAKS AND STATS: Biological ImplicationsAnnual Review of Immunology, 1998
- γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteinsNature, 1985
- Minor salivary gland involvement in Sjögren's syndromeOral Surgery, Oral Medicine, Oral Pathology, 1974